The National Institute of Health and Care Excellence (NICE) in a final decision recommended routine use of Kadcyla (ado-trastuzumab emtansine)...
This is a Phase III, randomized, multicenter, international, 2-arm, open-label clinical trial designed to compare the safety and efficacy of trastuzumab emtansine (T-DM1) with that of capecitabine + lapatinib in participants with...
Seagen Inc. announced data from the Phase III HER2CLIMB-02 clinical trial of Tukysa (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla)
Seattle Genetics, Inc. announced dosing of the first patient in HER2CLIMB-02, a randomized phase III clinical trial evaluating investigational agent...
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Tukysa (tucatinib + trastuzumab + capecitabine), from Seagen, for the treatment of advanced HER2-positive breast cancer.
This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in...
The Phase II/III GATSBY trial, designed to support a new indication for Kadcyla (ado-trastuzumab emtansine) from Roche + ImmunoGen in...
The UK's NICE has announced that Kadcyla (trastuzumab emtansine), from Roche, is too expensive for routine funding on the NHS...
Seattle Genetics, Inc.has announced that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for tucatinib, in combination...